tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Sep 16;10(9):1538.
doi: 10.3390/vaccines10091538.
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Hong-Yu Liang[SUP] 1 [/SUP], Yuyan Wu[SUP] 2 3 [/SUP], Vicky Yau[SUP] 4 [/SUP], Huan-Xin Yin[SUP] 1 [/SUP], Scott Lowe[SUP] 5 [/SUP], Rachel Bentley[SUP] 5 [/SUP], Mubashir Ayaz Ahmed[SUP] 6 [/SUP], Wenjing Zhao[SUP] 7 [/SUP], Chenyu Sun[SUP] 7 [/SUP]
Affiliations
Abstract
Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants.
Keywords: COVID-19; SARS-CoV-2 variants; molecular therapeutic target; vaccines.
. 2022 Sep 16;10(9):1538.
doi: 10.3390/vaccines10091538.
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Hong-Yu Liang[SUP] 1 [/SUP], Yuyan Wu[SUP] 2 3 [/SUP], Vicky Yau[SUP] 4 [/SUP], Huan-Xin Yin[SUP] 1 [/SUP], Scott Lowe[SUP] 5 [/SUP], Rachel Bentley[SUP] 5 [/SUP], Mubashir Ayaz Ahmed[SUP] 6 [/SUP], Wenjing Zhao[SUP] 7 [/SUP], Chenyu Sun[SUP] 7 [/SUP]
Affiliations
- PMID: 36146616
- DOI: 10.3390/vaccines10091538
Abstract
Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants.
Keywords: COVID-19; SARS-CoV-2 variants; molecular therapeutic target; vaccines.